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Resistance to β-lactams in Enterobacteriaceae has been increasing worldwide.
This study aimed to determine the frequency of β-lactamase genes and antibiotic
resistance rates of 140 extended-spectrum β-lactamase (ESBL)-producing Escherichia
coli isolates obtained from urinary tract infection in Ordu Province, Turkey. Isolates
were identiﬁed by classic methods and by automated system. ESBL production was
conﬁrmed by double disk synergy test and antimicrobial susceptibility was investigated
by disk diffusionmethod. All isolates were screened for β-lactamase coding genes from
three groups (A, B, andD) by polymerase chain reaction. The highest rate of susceptible
isolateswas observed for imipenem (IPM, 99.3%) and ertapenem (ETP, 97.9%), and the
highest rate of resistant isolates was observed for cefuroxime (97.9%), ceftriaxone
(97.2%), and cefazolin (90.7%). In our study, blaCTX-M1-like group was the most
prevalent β-lactamase (n = 109), followed by blaTEM (n = 68), blaCTX-M2 (n = 22), and
blaSHV (n = 2). By contrast to low resistance rate to IPM and ETP, we determined
blaNDM in 31 isolates (22.1%). In co-prevalence of blaNDM-1 and ESBL-coding genes, a
low carbapenem resistancewas determined.We can conﬁrm that blaCTX-M1-types are still
the most frequent β-lactamase coding gene in Turkey. Our study showed the highest
prevalence of blaNDM-1 metallo-β-lactamase coding gene in ESBL-producing E. coli.
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Introduction
Escherichia coli is known as one of the most predominant organisms
causing urinary tract infections (UTIs), which are very common reason for
consultation and antibiotic prescription in practice [1]. The number of β-lactamase
and especially extended-spectrum β-lactamase (ESBL)-producing strains is in-
creasing around the world. The variants and types of ESBL enzymes have
occurred due to many reasons, one of them is selective pressure caused by the
common antibiotic use since the 1980s and they are becoming a signiﬁcant
problem for the whole world [2]. ESBL-positive strains are increasingly isolated
from the community-acquired urinary system infections in addition to nosocomial
infections [3]. ESBL-producing members of Enterobacteriaceae are resistant to
penicillins, cephalosporins, and aztreonam (ATM). They frequently develop
resistance to aminoglycosides, trimethoprim–sulfamethoxazole (SXT), and qui-
nolones [4]. ESBL-producing microrganisms, such as Klebsiella pneumoniae,
E. coli, Morganella morganii, Serratia marcescens, Shigella dysenteriae, Enter-
obacter spp., Salmonella, Proteus, Citrobacter, and Pseudomonas aeruginosa
have been reported from many countries [5].
Currently, more than 450 ESBL variant β-lactamase enzymes with
different structures have been reported and the most important enzymes of
them are TEM, SHV, CTX-M, PER, GES, VEB, TLA, BES, and OXA
β-lactamases. The ESBLs are grouped into four classes as A, B, C, and D
enzymes. Class B enzymes are Zn-metallo enzymes, whereas enzymes of
classes A, C, and D are active site serine enzymes. TEM, SHV, and CTX-
M enzymes are in the class A ESBLs. While the TEM and SHV enzymes are the
major types, the CTX-M-type enzymes have emerged among these organisms
and CTX-M producing strains have a worldwide dissemination. CTX-M-type
β-lactamases have been classiﬁed into ﬁve groups 1, 2, 8, 9, and 25/26
according to their amino acid sequence similarities [6]. While group 1 includes
CTX-M-1, -3, -10, -11, -12, -15, -22, -23, -27, -28, -29, -30, -32, -33, -34, -36,
-37, and -42, and group 2 includes CTX-M-2, -4, -5, -6, -7, -20, -31, -35, and
Toho-1 [7]. The increasing prevalence of TEM, SHV, and CTX-M-type of
ESBLs poses an important threat to the clinical use of third-generation
cephalosporins for the treatment of serious infections. Determination of the
genes encoding for ESBLs by polymerase chain reaction (PCR) and sequencing
can provide useful information about their molecular epidemiology and risk
factors associated with these infectious diseases.
Africa and the Middle East have experienced a number of outbreaks of
ESBL-producing infections. Several studies demonstrated that CTX-M-type
ESBLs are more dominant in some countries including China, India, Japan,
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Korea, Malaysia, and Taiwan revealing ESBL-producing strains ranges from 30%
to 40% [8]. In a meta-analysis from Turkey, a lower than 20% ESBL rate was
found [9]. In another study from Hungary, the predominant gene of CTX-M-15 in
ESBL-producing isolates was reported [10]. Molecular characterization of ESBLs
was examined in E. coli isolates from 10 centers between the years 2011 and 2012.
The resistance against carbapenems in bacteria is mostly related to carbapene-
mases such as oxacillinases carbapenem-hydrolyzing class D β-lactamases
encoded by blaOXA genes, metallo-β-lactamases (MBLs) of IMP, VIM, and NDM
types, and carbapenemases of Ambler class A as KPC and GES [11]. The aim of
this study was to determine the prevalence of ESBL-producing E. coli, their drug
resistance pattern to commonly used antibiotics in medical practice, and
β-lactamase coding genes in these multidrug resistant isolates of urine samples
taken from patients diagnosed with UTIs.
Materials and Methods
Bacterial strains and antimicrobial susceptibility test
One hundred and forty ESBL-positive E. coli isolates were isolated from
urine cultures in the Medical Microbiology Laboratory of Ordu Training and
Research Hospital between August 2014 and April 2015 and they were described
according to Clinical and Laboratory Standards Institute (CLSI) criteria [12].
Identiﬁcation of isolates taken from adult and pediatric patients attending a variety
of clinics was completed by using classic methods and by Vitek-2Compact
(bioMérieux, France) automated system. Isolates were stored in glcyerol Luria–
Bertani Broth medium at−80 °C until the day of study. Antimicrobial susceptibility
tests were performed by disk diffusion method (Oxoid, UK) using ampicillin (AM),
sulbactam/ampicillin, amoxicillin–clavulanic acid (AMC), ceftazidime (CAZ),
ceftriaxone (CTX), cefuroxime (CXM), cefazolin (CZ), cefepime (FEP), gentami-
cin (GN), tobramycin, levoﬂoxacin (LEV), ciproﬂoxacin (CIP), nitrofurantoin (F),
tetracycline (TE), ertapenem (ETP), imipenem (IPM), and SXT antibiotic disks and
the results were evaluated according to the CLSI guidelines [12].
The detection of ESBLs
Phenotypic ESBL production was conﬁrmed by double disk synergy test.
MHA media were seeded with a swab with E. coli strains on 0.5 McFarland
prepared suspension and left at room temperature for 15 min. An AMC (20/10 μg)
disk was placed in the center with CAZ (30 μg/disk), CTX (CRO; 30 μg/disk),
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cefotaxime (CTX; 30 μg/disk), and ATM (30 μg/disk) disks placed around the
edges 25–30 mm from the center. Results were assessed after 18–24 h incubation
at 35 °C. This phenotypic ESBL screening test is based on the demonstration of a
synergy image between AMC and cefotaxime, CAZ, and ATM, according to the
guidelines of the CLSI. E. coli ATCC 25922 was used for control strain.
Multiplex PCR for detection of blaOXA and blaCTX-M genes
GenomicDNAswere puriﬁed fromovernight bacterial culture grown in 3mL
of Luria–Bertani broth using theWizard Genomic DNA Puriﬁcation Kit (Promega,
Madison,WI, USA) following themanufacturer’s instructions.Multiplex PCRwas
used to detectblaOXA-23-24-51 and 58-like andblaCTX-M-1/M-2 genes using primers listed
in Table I. PCRs were performed in a ﬁnal volume of 50 μL and included 5 μL of
genomicDNA,20pMof eachprimer, 10μLof 10Xpolymerase activity buffer, 3μL
of 25 mM MgCl2, 200 μM of each deoxynucleotide triphosphates (dNTPs), and
1.5 U of Taq Polymerase (Fermentas Thermo Fisher Scientiﬁc Inc., Waltham,
USA). PCR ampliﬁcation was performed using initial denaturation at 94 °C for
3 min followed by 30 cycles of 25 s at 94 °C, 40 s at 52 °C, and 50 s at 72 °C for
blaOXA genes and initial denaturation at 95 °C for 2 min followed by 30 cycles of
1 min at 95 °C, 1 min at 55 °C, and 1 min at 72 °C for blaCTX-M-1/M-2 genes with a
ﬁnal extension of 5 min at 72 °C. All PCR results were analyzed on 1% agarose
containing 0.5mg/L ethidiumbromide, subsequently visualized underUV light and
evaluated according to their molecular size.
PCR ampliﬁcations of ESBL and MBL resistance genes
The primers and PCR ampliﬁcation conditions used to detect ESBLs and
MBLs genes are shown in Table I. The reactions were performed in 50 μL ﬁnal
reaction volume using 5 μL of genomic DNA, 20 pM of each primer, 5 μL of
reaction buffer, 3 μL of 25 mM MgCl2, 200 μL of dNTPs, and 1 U Go Taq
Polymerase (Fermentas Thermo Fisher Scientiﬁc Inc., Waltham, USA). The
results were run as above and evaluated according to their molecular size and
PCR results of control groups, which were deﬁned as β-lactamase gene carrier
bacteria in the earlier studies [18–20]. Positive PCR products except
blaOXA-23-24-51-58, blaCTX-M1/M2, blaTEM, and blaSHV were sent to Macrogen Inc.,
Seoul, Korea, to sequence by using the same primers used in PCR reactions.
Sequencing results were analyzed using the alignment search tool BLAST (http://
www.ncbi.nlm.nih.gov/BLAST) and the multiple sequence alignment program
CLUSTALW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
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Results
Isolates were obtained from 140 urine samples from 64 pediatric and 76
adult patients. The study group was comprised of 94 females and 46 males with the
mean pediatric age of 11.4± 3.8 years and the mean adult age of 38.6± 14.8
years. Of these isolates, 18 were from hospitalized patients with 122 from clinic
outpatients, 7 (5%) intensive care, 43 (30.7%) pediatric, 23 (16.4%) urology, 18
(12.9%) emergency service, 13 (9.3%) infectious diseases, and 36 (25.7%) from
other departments. 140 ESBL-positive urine isolates were susceptible to the
following antibiotics: IPM with 99.3% and ETP with 99.7%, while the most
resistant isolates were against CXM (97.9%), CTX (97.2%), and CZ (90.7%),
respectively. All strains were found to be AM resistant. The susceptibility rates of
E.coli strains showing multiple drug resistance for all antibiotics tested are shown
in Table II.
According to PCR results, blaCTX-M1 was the most prevalent β-lactamase
77.8% (109/140), followed by blaTEM 48.6% (68/140), blaCTX-M2 15.7%
(22/140), and blaSHV 1.42% (2/140). More speciﬁcally, we determined blaNDM
in 31 isolates (22.1%) and they were all conﬁrmed as blaNDM-1 variant according
to the sequencing result. No other β-lactamases were identiﬁed among the
samples.
Table II. Antibiotic resistance rates of ESBL-producing E. coli
Antibiotics
Susceptible,
n (%)
Intermediate,
n (%)
Resistance,
n (%)
Ampicillin – – 140 (100%)
Sulbactam–ampicillin 23 (16.4%) 41 (29.3%) 76 (54.3%)
Amoxicillin–clavulanic
acid
16 (11.4%) 28 (20.0%) 96 (68.6%)
Ceftazidime 3 (2.1%) 54 (38.6%) 83 (59.3%)
Ceftriaxone 3 (2.1%) 1 (0.7%) 136 (97.2%)
Cefuroxime 1 (0.7%) 2 (1.4%) 137 (97.9%)
Cefazolin 13 (9.3%) – 127 (90.7%)
Cefepime 5 (3.6%) 112 (80.0%) 23 (16.4%)
Gentamicin 107 (76.4%) – 33 (23.6%)
Tobramycin 72 (51.4%) 3 (2.1%) 65 (46.5%)
Levoﬂoxacin 63 (45.0%) – 77 (55.0%)
Ciproﬂoxacin 59 (42.1%) – 81 (57.9%)
Nitrofurantoin 109 (77.9%) 24 (17.1%) 7 (5.0%)
Tetracycline 45 (32.1%) – 95 (67.9%)
Ertapenem 137 (97.9%) – 3 (2.1%)
Imipenem 139 (99.3%) 1 (0.7%) –
Trimethoprim–
sulfamethoxazole
49 (35%) – 91 (65%)
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Discussion
Characteristics of antimicrobial resistance show differences among regions,
hospitals, and even departments. Although wild-type E. coli strains are susceptible
to commonly used antimicrobial agents in the treatment of UTIs, antibiotic
resistance in uropathogenic E. coli infections is increasing worldwide. Some
factors such as common use and misuse of antibiotics both in hospitals by health
professionals and in the community by self-prescription, and inadequate antimi-
crobial surveillance programs are the reasons for increasing bacterial resistance
rates [21]. The susceptibility of ESBL-producing E. coli isolates to broad spectrum
cefalosporins shows variety. In an earlier study from Turkey, all strains were
identiﬁed to be susceptible to IPM, meropenem, and amikacin and all isolates were
observed to be resistant to cefotaxime and CTX. Susceptibility rates to cefoxitin,
ETP, cefoperazone/sulbactam, piperacillin/tazobactam, GN, CIP, FEP, AMC,
ATM, and CAZ were 96%, 83%, 63%, 61%, 50%, 41%, 25%, 21%, 20%, and
18%, respectively [22]. In recent years, carbapenem resistance has been encoun-
tered in ESBL-producing E. coli from Turkey and some studies found 100%
susceptibility for meropenem and IPM and varying rates of ETP susceptibility
(from 99.2% to 83%) for ESBL-producing E. coli strains [23, 24]. In our study,
similar to other studies, the isolates were mostly susceptible to IPM at 99.3% and
ETP at 99.7%, while they were mostly resistant against cefuroxime-axetil (99.3%),
CXM (97.9%), CTX (97.2%), and CZ (90.7%).
TEM and SHV types of ESBL-producing organisms are primarily nosoco-
mial and they are produced by many enteric bacteria. Especially CTX-M type has
been increasingly reported worldwide. CTX-M-type ESBL-producing E. coli
pathogens have become an important cause of community-onset blood stream
infections and UTIs [25]. The epidemiological characteristics of infections caused
by CTX-M-type ESBLs are different from the TEM or SHV type and they are
often isolated from the patients with community-onset infections. A study in
America in 2000 found a 25% rate of CTX-M type genes, this rate rose to 69% in
2004 and the most common one was CTX-M-15 followed by CTX-M-16, -8, and
-14 [26]. A study in Thailand identiﬁed the gene prevalence for CTX-M as 99.3%,
TEM as 77%, SHV as 3.8%, VEB-1 as 8.5%, and OXA-10 as 8.1% with PER and
GES genes not identiﬁed in any isolate [27]. Other studies in the world showed the
prevalences of blaTEM and blaSHV genes in E. coli were 46.4% and 11.2%,
respectively [28], and CTX-M types have been reported as the most frequent
ESBLs (65%) among Enterobacteriaceae isolates [29].The prevalences of blaTEM
and blaSHV were 65.5% and 15%, respectively. In a study of patients with ESBL-
producing E. coli, 85.4% of isolates contained a CTX-M ESBL gene [25]. Another
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study demonstrated that CTX-M-14 was the most common ESBL among E. coli
isolates, while SHV was the predominant among K. pneumoniae isolates. It also
showed the co-existence of two or more kinds of ESBL in a single isolate
frequently [30].
In Turkey, β-lactamase coding gene rates for blaCTX-M, blaTEM, blaOXA-2,
blaPER, blaSHV, and blaOXA-10 groups were found in E. coli isolates as 89.5%,
59.2%, 15.8%, 14.5%, 11.8%, and 3.9%, respectively. No blaGES and blaVEB
β-lactamase genes were encountered in any isolate and 1.3% of the investigated
genes were identiﬁed in all the isolates. While blaTEM and blaCTX-M genes were
detected together in 25 isolates, blaCTX-M and blaTEM genes were detected alone
in 20 and 2 isolates. blaSHV genes were not identiﬁed alone in any isolate [22].
In a different study from 10 hospitals, blaCTX-M1 was the most prevalent
β-lactamase (83.18%), followed by blaTEM (44.09%), blaCTX-M2 (31.81%), and
blaSHV (1.81%) [13]. In this study, none of the isolates were found to have
blaVEB, blaGES, blaPER, blaKPC, blaVIM, and blaIMP positivity. According to the
PCR result, blaCTX-M1 was the most prevalent β-lactamase (77.8%), followed
by blaTEM (48.6%), blaCTX-M2 (15.7%), and blaSHV (1.42%). According to
these results, more speciﬁcally blaNDM-1 type MBL coding gene was deter-
mined in 31 isolates (22.1%). To the best of our knowledge, this is the ﬁrst
record showing the highest prevalence of blaNDM-1 in ESBL-producing E. coli
from Turkey. NDM-type enzymes are carbapenemases and they hydrolyze
carbapenems such as IPM, meropenem, ETP, and doripenem. According to the
high prevalence of blaNDM-1 variants in isolates, high rate of sensitivity to IPM
and ETP for isolates was determined. According to CLSI, Minimal _Inhibitory
Concentration (MIC) values ≤1 and 0.5 μg/mL are accepted as sensitive for
IPM and ETP, respectively and Nordmann reported that isolates from Enter-
obacteriaceae carrying blaNDM-1 have MIC values 0.5→32 for IPM and
0.38→32 for ETP. This means that there are some other factors affecting the
resistance against antimicrobials besides carbapenemases [31]. The use of some
kind of antibiotics such as ﬂuoroquinolones might facilitate the widespread
dissemination of ESBL-producing bacteria in the healthcare setting [32].
The important dissemination of ESBL and carbapenemases-producing
E. coli has lead to a decrease in therapeutic options. The ﬁndings indicate that
CTX-M1 type β-lactamases are the most frequent among ESBL-producing E. coli
isolates in our hospital. Although TEM rapidly grow in Turkey, CTX-M1 is still
the most frequent CTX-M type β-lactamases. Updates of trends for regional
epidemiological data on the prevalence of the β-lactamase genes and antimicrobial
resistance are crucial in order to promote appropriate antimicrobial therapy as well
as an effective infection control and clinical care management.
138 ÇETINKOL ET AL.
Acta Microbiologica et Immunologica Hungarica 64, 2017
Acknowledgements
This study was partially supported by a grant from the Scientiﬁc and
Technical Research Council of Turkey (TUB_ITAK-113Z054) and Recep Tayyip
Erdog˘an University (BAP-2014.102.03.02 and BAP-2014.102.03.03).
Conﬂict of Interest
The authors declare that they have no conﬂict of interest.
References
1. Schito, G. C., Naber, K. G., Botto, H., Palou, J., Mazzei, T., Gualco, L., Marchese, A.:
The ARESC study: An international survey on the antimicrobial resistance of pathogens
involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34, 407–413
(2009).
2. Lautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H., Fishman, N. O.: Extended-
spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk
factors for infection and impact of resistance on outcomes. Clin Infect Dis 32, 1162–
1171 (2001).
3. Canto´n, R., Novais, A., Valverde, A., Machado, E., Peixe, L., Baquero, F., Coque, T. M.:
Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in
Europe. Clin Microbiol Infect 14, 144–153 (2008).
4. Rodríguez-Ban˜o, J., Navarro, M. D., Romero, L., Martínez-Martínez, L., Muniain, M. A.,
Perea, E. J., Pérez-Cano, R., Pascual, A.: Epidemiology and clinical features of infections
caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized
patients. J Clin Microbiol 42, 1089–1094 (2004).
5. Hanson, N. D., Moland, E. S., Hossain, A., Neville, S. A., Gosbell, I. B., Thomson, K. S.:
Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and
OXA-30 β-lactamases. J Antimicrob Chemother 49, 1011–1014 (2002).
6. Bonnet, R.: Growing group of extended-spectrum β-lactamases: The CTX-M enzymes.
Antimicrob Agents Chemother 48, 1–14 (2004).
7. Eckert, C., Gautier, V., Saladin-Allard, M., Hidri, N., Verdet, C., Ould-Hocine, Z.,
Barnaud, G., Delisle, F., Rossier, A., Lambert, T., Philippon, A., Arlet, G.: Dissemination
of CTX-M-Type β-Lactamases among clinical isolates of Enterobacteriaceae in Paris,
France. Antimicrob Agents Chemother 48, 1249–1255 (2004).
8. Antony, S. J.: The changing epidemiology of extended spectrum Beta-lactamases (ESBL)
infections of the urinary tract focusing on clinical resistance and therapeutic options. In
Nikibakhsh, A. A. (ed): Clinical Management of Complicated Urinary Tract Infection.
InTech, Rijeka, Croatia, 2011, pp. 19–22.
9. Aykan, S¸. B., Çiftçi, I. H.: Antibiotic resistance patterns of Escherichia coli strains isolated
from urine cultures in Turkey: A meta-analysis. Mikrobiyol Bul 47, 603–618 (2013).
β-LACTAMASE GENES IN ESBL-POSITIVE E. COLI 139
Acta Microbiologica et Immunologica Hungarica 64, 2017
10. Melegh, S., Schneider, G., Horváth, M., Jakab, F., Emődy, L., Tigyi, Z.: Identiﬁcation and
characterization of CTX-M-15 producingKlebsiella pneumoniae clone ST101 in a Hungari-
an university teaching hospital. Acta Microbiol Immunol Hung 62, 233–245 (2015).
11. Poirel, L., Naas, T., Nordmann, P.: Diversity, epidemiology, and genetics of class D
β-lactamases. Antimicrob Agents Chemother 54, 24–38 (2010).
12. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicro-
bial susceptibility testing. 24th Informational Supplement (M100-S24). CLSI, Wayne, PA
(2014).
13. Cicek, C. A., Saral, A., Ozad, A. O., Yasar, E., Cizmeci, Z., Balci, P. O., Sari, F., Firat, M.,
Altintop, Y. A., Ak, S., Caliskan, A., Yildiz, N., Sancaktar, M., Budak, E. E., Erturk, A.,
Ozgumus, O. B., Sandalli, C.: Nationwide study of Escherichia coli producing extended-
spectrum β-lactamases TEM, SHV, and CTX-M in Turkey. J Antibiot 66, 647–650 (2013).
14. Xu, L., Ensor, V., Gossain, S., Nye, K., Hawkey, P.: Rapid and simple detection of
blaCTX-M genes by multiplex PCR assay. J Med Microbiol 54, 1183–1187 (2005).
15. Moubareck, C., Brémont, S., Conroy, M. C., Courvalin, P., Lambert, T.: GES-11, a
novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents
Chemother 58, 3579–3581 (2009).
16. Schechner, V., Straus-Robinson, K., Schwartz, D., Pfeffer, I., Tarabeia, J., Moskovich, R.,
Chmelnitsky, I., Schwaber, M. J., Carmeli, Y., Navon-Venezia, S.: Evaluation of PCR-
based testing for surveillance of KPC-producing carbapenem-resistant members of the
Enterobacteriaceae family. J Clin Microbiol 47, 3261–3265 (2009).
17. Jeon, B. C., Jeong, S. H., Bae, I. K., Kwon, S. B., Lee, K., Young, D., Lee, J. H., Song, J. S.,
Lee, S. H.: Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter
baumannii producing the OXA-23 β-lactamase in Korea. J Clin Microbiol 43, 2241–2245
(2005).
18. Iraz, M., Düzgün, A. Ö., Sandallı, C., Doymaz, M. Z., Akkoyunlu, Y., Saral, A., Peleg,
A. Y., Özgümüs¸, O. B., Beris¸, F. S¸., Karaog˘lu, H., Çiçek, A. Ç.: Distribution of β-lactamase
genes among carbapenem-resistant Klebsiella pneumoniae strains isolated from patients in
Turkey. Ann Lab Med 35, 595–601 (2015).
19. Woodford, N., Ellington, M. J., Coelho, J. M., Turton, J. F., Ward, M. E., Brown, S.,
Amyes, S. G., Livermore, D. M.: Multiplex PCR for genes encoding prevalent OXA
carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27, 351–353 (2006).
20. Cicek, A. Ç., Saral, A., Iraz, M., Ceylan, A., Duzgun, A. O., Peleg, A. Y., Sandallı, C.:
OXA- and GESF-type β-lactamases predominate in extensively drug-resistant Acineto-
bacter baumannii isolates from a Turkish University Hospital. Clin Microbiol Infect 20,
410–415 (2014).
21. El bouamri, M. C., Arsalane, L., Zerouali, K., Katfy, K., El kamouni, Y., Zouhair, S.:
Molecular characterization of extended spectrum β-lactamase-producing Escherichia coli
in a university hospital in Morocco, North Africa. Afr J Urol 21, 161–166 (2015).
22. Görgeç, S., Kuzucu, Ç., Otlu, B., Yetkin, F., Ersoy, Y.: Investigation of beta-lactamase
genes and clonal relationship among the extended-spectrum beta-lactamase producing
nosocomial Escherichia coli isolates. Mikrobiyol Bul 49, 15–25 (2015).
23. Kiremitci, A., Dinleyici, E. C., Erben, N., Durmaz, G., Yargic, Z. A., Aybey, A. D., Usluer,
G.: In vitro activity of ertapenem and other carbapenems against extended-spectrum
β-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a
tertiary care center in Turkey. Expert Opin Pharmacother 9, 1441–1449 (2008).
140 ÇETINKOL ET AL.
Acta Microbiologica et Immunologica Hungarica 64, 2017
24. Kuzucu, Ç., Yetkin, F., Görgeç, S., Ersoy, Y.: Investigation of the susceptibilities of
extended-spectrum β-lactamase producing Escherichia coli and Klebsiella spp. strains to
ertapenem and other carbapenems. Mikrobiyol Bul 45, 28–35 (2011).
25. Hayakawa, K., Gattu, S., Marchaim, D., Bhargava, A., Palla, M., Alshabani, K., Gudur,
U. M., Pulluru, H., Bathina, P., Sundaragiri, P. R., Sarkar, M., Kakarlapudi, H., Ramasamy,
B., Nanjireddy, P., Mohin, S., Dasagi, M., Datla, S., Kuchipudi, V., Reddy, S., Shahani, S.,
Upputuri, V., Marrey, S., Gannamani, V., Madhanagopal, N., Annangi, S., Sudha, B.,
Muppavarapu, K. S., Moshos, J. A., Lephart, P. R., Pogue, J. M., Bush, K., Kaye, K. S.:
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type
extended-spectrum β-lactamase in a large U.S. Medical Center. Antimicrob Agents
Chemother 57, 4010–4018 (2013).
26. Lewis, J. S., Herrera, M., Wickes, B., Patterson, J. E., Jorgensen, J. H.: First report of the
emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant
ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 51, 4015–4021
(2007).
27. Kiratisin, P., Apisarnthanarak, A., Laesripa, C., Saifon, P.: Molecular characterization and
epidemiology of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella
pneumoniae isolates causing healthcare-associated infection in Thailand, where the CTX-M
family is endemic. Antimicrob Agents Chemother 52, 2818–2824 (2008).
28. Shahcheraghi, F., Nikbin, V. S., Feizabadi, M. M.: Prevalence of ESBLs genes among
multidrug-resistant isolates of Pseudomonas aeruginosa isolated from patients in Tehran.
Microb Drug Resist 15, 37–39 (2009).
29. Ben-Ami, R., Rodríguez-Ban˜o, J., Arslan, H., Pitout, J. D., Quentin, C., Calbo, E. S., Azap,
O. K., Arpin, C., Pascual, A., Livermore, D. M., Garau, J., Carmeli, Y.: A multinational
survey of risk factors for infection with extended-spectrum β-lactamase-producing Enter-
obacteriaceae in nonhospitalized patients. Clin Infect Dis 49, 682–690 (2009).
30. Lin, C. F., Hsu, S. K., Chen, C. H., Huang, J. R., Lo, H. H.: Genotypic detection and
molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli
and Klebsiella pneumoniae in a regional hospital in central Taiwan. J Med Microbiol 59,
665–671 (2010).
31. Nordmann, P., Gniadkowski, M., Giske, C. G., Poirel, L., Woodford, N., Miriagou, V., The
European Network on Carbapenemases: Identiﬁcation and screening of carbapenemase-
producing Enterobacteriaceae. Clin Microbiol Infect 18, 432–438 (2012).
32. Füzi, M.: Has the use of ﬂuoroquinolone facilitated the widespread dissemination of
methicllin-resistant Staphylococcus aureus and extended spectrum β-lactamase-producing
Klebsiella pneumoniae in the healthcare setting? Acta Microbiol Immunol Hung 61,
399–405 (2014).
β-LACTAMASE GENES IN ESBL-POSITIVE E. COLI 141
Acta Microbiologica et Immunologica Hungarica 64, 2017
